Circle Pharma Inc.

06/02/2025 | Press release | Archived content

A Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class Cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Circle Pharma Inc. published this content on June 02, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 02, 2026 at 14:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]